Summary
Boston Scientific Corporation reported strong top-line growth in the third quarter of 2017, with net sales increasing by 5.6% to $2.22 billion compared to the prior year. On an operational basis, excluding currency fluctuations, net sales grew by 5.7%. The company also showed improved profitability, with net income rising to $283 million from $228 million in the same period last year. This growth was driven by solid performance across key segments, particularly MedSurg and Interventional Cardiology. Acquisitions, including Symetis SA and Apama Medical Inc., are being integrated and are expected to contribute to future growth. The company's financial health remains robust, supported by operating cash flow of $554 million for the first nine months of the year. Management also highlighted ongoing strategic initiatives, including investments in R&D and expansion into emerging markets. While the company faces ongoing litigation and regulatory matters, particularly concerning transvaginal surgical mesh products, management believes its accruals are adequate and its overall financial position is strong enough to meet its obligations for the next twelve months. Key challenges include managing patent litigation and adapting to evolving healthcare regulations.
Financial Highlights
50 data points| Revenue | $2.22B |
| Cost of Revenue | $637.00M |
| Gross Profit | $1.58B |
| SG&A Expenses | $800.00M |
| Operating Expenses | $1.21B |
| Operating Income | $377.00M |
| Interest Expense | $57.00M |
| Net Income | $283.00M |
| EPS (Basic) | $0.21 |
| EPS (Diluted) | $0.20 |
| Shares Outstanding (Basic) | 1.37B |
| Shares Outstanding (Diluted) | 1.39B |
Key Highlights
- 1Net sales increased by 5.6% to $2.22 billion in Q3 2017 compared to Q3 2016. Operational net sales grew by 5.7%.
- 2Net income increased to $283 million in Q3 2017, up from $228 million in Q3 2016, with diluted EPS at $0.20 compared to $0.17.
- 3Strong growth in the MedSurg segment (10.3% operational growth) and solid performance in Interventional Cardiology (4.2% operational growth) were key drivers.
- 4The company completed the acquisition of Symetis SA for approximately $430 million, adding to its structural heart business, and announced the acquisition of Apama Medical Inc.
- 5Operating cash flow for the first nine months of 2017 was $554 million, demonstrating healthy cash generation.
- 6The company remains compliant with its debt covenants, with a leverage ratio of 2.3 times, well below the 3.5 times maximum.
- 7Significant litigation remains, particularly for transvaginal surgical mesh products, with approximately 48,500 cases pending, though settlement agreements are in progress for a substantial number.